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Abstract
Background Patient selection for seizure prophylaxis after traumatic brain injury (TBI) and duration of anti-epileptic drug
treatment for patients with early post-traumatic seizures (PTS), remain plagued with uncertainty. In early 2017, a collaborative
group of neurosurgeons, neurologists, neurointensive care and rehabilitation medicine physicians was formed in the UKwith the
aim of assessing variability in current practice and gauging the degree of uncertainty to inform the design of future studies. Here
we present the results of a survey of clinicians managing patients with TBI in the UK and Ireland.
Materials and methods An online survey was developed and piloted. Following approval by the Academic Committee of the
Society of British Neurological Surgeons, it was distributed via appropriate electronic mailing lists.
Results One hundred and seventeen respondents answered the questionnaire, predominantly neurosurgeons (76%) from 30 (of
32) trauma-receiving hospitals in the UK and Ireland. Fifty-three percent of respondents do not routinely use seizure prophylaxis,
but 38% prescribe prophylaxis for one week. Sixty percent feel there is uncertainty regarding the use of seizure prophylaxis, and
71% would participate in further research to address this question. Sixty-two percent of respondents use levetiracetam for
treatment of seizures during the acute phase, and 42% continued for a total of 3 months. Overall, 90% were uncertain about
the duration of treatment for seizures, and 78% would participate in further research to address this question.
Conclusion The survey results demonstrate the variation in practice and uncertainty in both described aspects of management of
patients who have suffered a TBI. Themajority of respondents would want to participate in future research to help try and address
this critical issue, and this shows the importance and relevance of these two clinical questions.
This article is part of the Topical Collection on Brain Trauma
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00701-018-3683-9) contains supplementary
material, which is available to authorized users.
* Harry Mee
harrymee@nhs.net
1 Department of Clinical Neurosciences, University of Cambridge &
Addenbrooke’s Hospital, Cambridge, UK
2 Surgery theme, Cambridge Clinical Trials Unit, Cambridge, UK
3 Department of Neurosurgery, Royal London Hospital, London, UK
4 Neurosciences Critical Care Unit and Division of Anaesthesia,
University of Cambridge & Addenbrooke’s Hospital,
Cambridge, UK
5 School of Health and Related Research, University of Sheffield,
Sheffield, UK
6 Department of Biostatistics, University of Liverpool,
Merseyside, Liverpool, UK
7 Department of Neurosurgery, Queen Elizabeth Hospital,
Birmingham, UK
8 Department of Neurosurgery, The Walton Centre, Liverpool, UK
9 Department of Neurosurgery, University Hospital Southampton,
Southampton, UK
10 Department of Clinical and Experimental Epilepsy, UCL Institute of
Neurology, London, UK
11 Imperial Neurotrauma Centre, Department of Surgery & Cancer,
Imperial College, London, UK
12 Department of Molecular and Clinical Pharmacology, Institute of
Translational Medicine, University of Liverpool, Liverpool, UK
Acta Neurochirurgica
https://doi.org/10.1007/s00701-018-3683-9
Keywords Post-traumatic seizures . Traumatic brain injury . Anti-epilepticmedication . Seizure prophylaxis
Introduction
Traumatic brain injury (TBI) remains a significant public
health problem that can result in physical, cognitive, function-
al and psychosocial disabilities [7].
Post-traumatic seizures (PTS) are well recognised fol-
lowing TBI. They are typical, albeit somewhat arbitrarily,
classified as immediate (at time of impact), early (within
7 days post-TBI) or late (after 7 days) [5]. Seizures during
acute hospitalisation can lead to significant derangement
of brain physiology, contributing to secondary injury
through energetic crisis and/or intracranial hypertension
or even directly leading to brain herniation and death.
Additionally, PTS during acute hospitalisation has been
shown to be an independent risk factor for PTS within
12 and 24 months following TBI [9]. Late PTS can have
a negative impact on quality of life, return to work, return
to driving and can even result in death. The rationale for
seizure prophylaxis with an anti-epileptic drug (AED)
during acute hospitalisation is that the incidence of early
PTS in patients following severe TBI is as high as 14%
[12] and prevention of seizures can limit derangements in
brain physiology, lower the risk of herniation and death
and potentially prevent the development of late PTS.
However, AEDs have variable positive, negative or neu-
tral effects in both cognitive and behavioural domains [8].
They are also associated with some other side effects in-
cluding bone density loss, hepatotoxicity and Stevens-
Johnson Syndrome [4]. It is therefore essential to ensure
that AEDs are prescribed appropriately and for the opti-
mal duration following TBI.
Many studies of seizure prophylaxis pre-date the
availability of EEG monitoring in the ITU, and in the
light of evidence of the frequency of subclinical sei-
zures in TBI, this question would benefit from re-
evaluation [3]. Patients who develop PTS in the acute
phase after a TBI are typically started on an AED to
prevent further seizures. However, there is no high-
quality evidence regarding the optimal duration of treat-
ment for this group of patients.
There is a pressing need for high-quality evidence, and
a baseline understanding of clinical practice is an essential
pre-requisite for the design of an appropriate clinical trial.
In 2017, a collaborative group of neurosurgeons,
neurointensive care physicians and rehabilitation medi-
cine physicians was formed with the aim of examining
current practice patterns, gauging the degree of uncertain-
ty and thus designing relevant future studies on the use of
AEDs following TBI. It was agreed that a questionnaire
survey would be a pragmatic way of achieving the first
two objectives.
Materials and methods
In line with the above objectives, we developed and piloted a
questionnaire survey. Subsequently, the questionnaire survey
was approved by the academic committee of the Society of
British Neurological Surgeons (SBNS). A convenience sam-
ple of clinicians with interest in the management of patients
with TBI and/or seizures was asked to complete the survey. A
62 (53%)
41 (35%)
11 (9%)
3 (3%)
Do not rounely use
seizure prophylaxis
Leveracetam Phenytoin Valproate
Fig. 1 Responses to question:
‘Which anti-epileptic drug do you
use as first choice for seizure
prevention (i.e. the patient has not
had a seizure) in moderate to
severe traumatic brain injury
during the acute phase?’
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secure online survey tool was used to disseminate the ques-
tionnaires via the electronic mailing lists of the SBNS, British
Neurosurgical Trainees Association (BNTA) and included in
the Association of British Neurologists newsletter. The survey
was also promoted by the Twitter accounts of the SBNS
(@The_SBNS), BNTA (@e1v1m1), British Neurotrauma
Group (@bntg_uk), British Neurosurgical Trainee Research
Collaborative (@BNTRC) and Association of British
Neurologists (@theABN_Info).
Our target audience were clinicians who were in-
volved with the acute and long-term management of
TBI patients, who were linked with adult trauma-
receiving neurosurgical units. We disseminated the sur-
vey to neurousurgeons, intensive care medicine/anaes-
thesia, neurology, emergency medicine and rehabilitation
medicine. Due to the wide dissemination of the ques-
tionnaire through social media platforms, calculation of
the response rate is not possible; 95% confidence inter-
vals have been used and documented as (%-%) after the
figures.
Results
The online questionnaire was completed by 117 clinicians
from a range of specialties, but predominately neurosurgeon-
neurosurgery (n = 89, 76%), intensive care medicine/
anaesthesia (n = 24, 21%), neurology (n = 2, 2%), emergency
medicine and rehabilitation medicine (n = 1 each). The major-
ity of the respondents were consultants (n = 78, 67%), while
the remaining were trainees or fellows (n = 39, 33%). There
were respondents from 30 of the adult trauma-receiving neu-
rosurgical units, 29 in the UK and 1 from Ireland. There was at
least 1 response from a Consultant from 21/30 (66%) of the
adult receiving neurosurgical units. The questionnaire dissem-
inated can be found in the online supplementary material.
Seizure prophylaxis
Fifty-three percent (n = 62; 44–62%) of respondents do not
use seizure prophylaxis routinely compared to 47% (n = 55;
41 (35%)
12 (10%)
18 (15%)
7 (6%)
52 (44%)
32 (27%)
47 (40%)
13 (11%)
24 (21%)
 I never use seizure prophylaxis
GCS < 13
GCS < 9
Pupillary abnormalies
Contusions on CT
Haematoma (intra-axial or extra-axial) on CT
Depressed skull fracture on CT
Traumac subarachnoid haemorhage on CT
Need for Craniotomy
Fig. 2 Responses to question:
‘Which factors influence your
decision to start seizure
prophylaxis?’ (can select more
than one answer)
41 (35%)
44 (38%)
5 (4%)
11 (9%)
6 (5%)
2 (2%)
8 (7%)
I never use
seizure
prophylaxis
For a total of
7 days
For a total of
10 days
For a total of
14 days
Discharge
intensive
care
Discharge
neurosurg
ward
Other
Fig. 3 Responses to question: ‘If
you start seizure prophylaxis
during the acute phase, how long
do you continue (assuming that
no seizures occur)?’
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31–50%) who do so for patients with a moderate or severe
TBI during the acute phase (Fig. 1). Of those who use pro-
phylaxis, 75% (n = 41/55; 61–85%) chose levetiracetam over
phenytoin (n = 11/55; 20% (11–33%)) or valproate (n = 3/55;
5% (1–16%). When asked about factors influencing their de-
cision to start prophylaxis (Fig. 2), 65% of the respondents
(n = 76; 55–73%) selected at least one factor. The top five
factors influencing the decision to start seizure prophylaxis
are the presence of contusions on CT (n = 52), depressed skull
fracture (n = 47), intra-axial or extra-axial haematoma on CT
(n = 32), need for craniotomy (n = 24) and a GCS < 9 (n = 18).
When asked about the length of prophylaxis, the majority
(n = 44; 58% (29–47%)) prescribe prophylaxis for 7 days
(Fig. 3). Finally, the majority (n = 70; 60% (50–69%)) felt that
there is uncertainty/equipoise surrounding the use of seizure
prophylaxis (Fig. 4) with 71% (n = 83; 62–79%) stating that
they would participate in a randomised trial to address seizure
prophylaxis in moderate to severe TBI during the acute phase
(Fig. 5).
Treatment of early PTS
The majority of respondents (n = 72; 62% (52–70%)) use le-
vetiracetam for patients with PTS during the acute phase
(Fig. 6). Nearly one third (n = 35; 30% (22–39%)) use phe-
nytoin with valproate favoured by less than 10% (n = 8; 3–
13%). There was variation in the duration of treatment with
AEDs (Fig. 7), with 42% (n = 49; 33–51%) continuing treat-
ment for 3 months if no further seizures occur, 24% (n = 28;
17–33%) for 6 months, 10% (n = 12; 5–18%) for 12 months
and 12% (n = 14; 7–20%) tapering after discharge from the
hospital (Fig. 7). Ninety percent (n = 105; 82–94%) stated that
there is uncertainty regarding the optimal duration of treat-
ment with AEDs for PTS occurring during acute
hospitalisation (Fig. 8), with 78% (n = 91; 69–85%) stating
that they would participate in a randomised trial to address
duration of treatment (Fig. 9).
When respondents were asked to select the top priority for
future research in the field of PTS, 57% (n = 67; 48–66%)
70 (60%)
23 (20%) 23 (20%)
Yes No Maybe
Fig. 4 Responses to question:
‘Do you think that there is
uncertainty/equipoise about the
use (or not) of seizure prophylaxis
in moderate to severe traumatic
brain injury during the acute
phase?’
83 (71%)
9 (8%)
24 (21%)
Yes No Maybe
Fig. 5 Responses to question:
‘Would you participate in a
randomised trial to address
seizure prophylaxis in moderate
to severe traumatic brain injury
during the acute phase?’
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answered seizure prophylaxis, nearly one third (n = 37; 32%
(24–41%)) duration of treatment for PTS during the acute
phase, and 10% favoured research on the type of AEDs that
should be used (Fig. 10).
Discussion
The survey findings confirm that there is significant
variation in the practice across the UK and Ireland with
regard to the use of seizure prophylaxis and the dura-
tion of treatment with AEDs after early PTS. A
Cochrane review [14], concluded that there is ‘low-qual-
ity evidence that early treatment with an AED compared
with placebo or standard care reduced the risk of early
post-traumatic seizures’ and that ‘there was no evidence
to support a reduction in the risk of late seizures or
mortality’. Despite that, nearly half of the respondents
routinely use prophylactic AEDs (47%). The 2016
‘Brain Trauma Foundation’ guidelines [1] stated that
‘phenytoin is recommended to decrease the incidence
of early PTS, when the overall benefit is felt to out-
weigh the complications associated with such treatment’,
but concluded that ‘there was insufficient evidence to
support a Level I recommendation for the topic of
post-traumatic seizures’ and are calling for further trials.
The survey showed that the two most commonly used
AEDs, for prophylaxis or treatment, are levetiracetam and
phenytoin with the former having surpassed the latter in pop-
ularity. This reflects the findings of a recent survey of US
clinicians [10], which showed that 74% of the respondents
prefer levetiracetam for seizure prophylaxis, with only 10%
favouring phenytoin. A similar trend has also recently been
demonstrated in Europe [6].
Temkin et al. [12] demonstrated that phenytoin given
for 1-year versus placebo decreased early PTS (within
7 days) from 14.2% down to 3.6%, but seizure rate did
not vary after 7 days. Therefore, the available evidence,
so far, suggests prophylaxis treatment is beneficial for
reduction of early PTS only. Our study shows a variable
prophylaxis rate, with 52% not using prophylaxis rou-
tinely and 60% being uncertain about the use of pro-
phylaxis. A prospective, randomised, single-blinded
study by Szaflarski et al. [11] showed no difference
between the seizure rates of phenytoin or levetiracetam.
However, this was a small study, and it is noted that
further exploration is required. Due to its superior side
effect profile and the fact, there is no need for plasma
72 (61%)
35 (30%)
8 (7%)
1 (1%) 1 (1%)
Leveracetam Phenytoin Sodium Valproate Phenobarbitone Lamotrigine
Fig. 6 Responses to question:
‘Which anti-epileptic drug do you
use for a patient with traumatic
brain injury who has had
seizure(s) during the acute
phase?’
14 (12%)
49 (42%)
28 (24%)
12 (10%)
14 (12%)
Taper aer
discharge
3 months if no
further seizures
6 months if no
further seizures
12 months if no
further seizures
Other
Fig. 7 Responses to question: ‘If
you initiate treatment with anti-
epileptics for seizures in the acute
phase after traumatic brain injury,
how long do you continue for?’
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monitoring levetiracetam has become the AED of
choice, with 58% of respondents choosing to use this
drug.
PTS during and after acute hospitalisation are often
harmful. Recurrent PTS post-TBI can negatively impact
on quality of life, return to work/driving and can even
lead to death. PTS during acute hospitalisation has been
shown to be an independent risk factor for PTS within
12 and 24 months following TBI [9]. AEDs are the
mainstay of treatment for patients with PTS but are
associated with side effects that, if serious, can nega-
tively impact on quality of life, cognition and general
health [4, 8]. Patients with acute PTS are typically
started on an AED to prevent seizure recurrence. The
optimal duration of treatment remains unclear [13] but
as TBI carries an increased risk of epilepsy as a conse-
quence of recurrent seizures [2], further trials are neces-
sary to try and answer these important questions.
Although we acknowledge there are limitations in
questionnaire surveys and appreciate that the response
rate of online surveys is not possible to know due to
the multiple channels of dissemination, we feel that hav-
ing over 100 responses from the majority of adult
trauma-receiving neurosurgical units in the UK and
Ireland provides a reasonable overview of the current
practice patterns. A further limitation is the fact that
there were only Consultant responses from two thirds
of the units; however, trainees and speciality doctors
in these units play an active role in the management
of TBI patients and PTS and therefore the value of
having their views cannot be ignored and commonly
will reflect the views of the consultants.
The survey results demonstrate that there is significant un-
certainty as to the duration of treatment of acute PTS, and also,
uncertainty surrounding whether prophylaxis for PTS should
be given. The results of the survey are not surprising as they
underline the known uncertainity of current practices across
the UK and Ireland and confirms the need for future research
around this topic.
The uncertainties are most likely due to the lack of high-
quality data investigating the duration of treatment and pro-
phylaxis of PTS. The fact that the majority of the respondents
105 (90%)
4 (3%)
8 (7%)
Yes No Maybe
Fig. 8 Responses to question:
‘Do you think that there is
uncertainty about the duration of
treatment with anti-epileptic
drugs for seizures occurring in the
acute phase after traumatic brain
injury?’
91 (78%)
4 (3%)
20 (17%)
Yes No Maybe
Fig. 9 Responses to question:
‘Would you participate in a
randomised trial to address
duration of treatment with anti-
epileptic drugs for seizures
occurring in the acute phase after
traumatic brain injury?’
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are willing to collaborate on future studies highlights the im-
portance of this subject to the community of clinicians caring
for TBI patients in the UK.
Conclusions
The current paper demonstrates the variation in practice and
uncertainty in both described aspects of the management of
patients with TBI. The majority of respondents would want to
participate in future research to help try and address these
issues, and this shows the importance and relevance of these
two clinical questions. Ultimately, class I evidence is neces-
sary to provide clinicians with a better evidence base and
achieve further improvements in the outcome of patients with
TBI and PTS.
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Comments
We have read with much interest the recent paper by Mee et al. [1].
The authors presented the results of a survey of clinicians managing
patients with traumatic brain injury (TBI) in the UK and Ireland. The
survey results demonstrate the variation in practice and uncertainty both
in patient selection for seizure prophylaxis and in the duration of anti-
epileptic drug treatment in early post-traumatic seizures (PTS). Moreover,
it clearly shows the necessity of future research on the topic.
First, we would like to congratulate the authors for the well-written
presentation of this survey results as we believe they are very informative
and, providing a practical overview of the current clinical practice, high-
light the uncertainties in the management of PTS. Moreover, we would
like to stress further the real and strong necessity of additional effort in
this field, most of all in the light of the recent gain in understanding of
underlying mechanisms subtending seizures. In respect of great reso-
nance in the field is the update of Classification of the Epilepsies recently
performed by the International League Against Epilepsy (ILAE) [2]. The
new classification incorporates etiology along each stage, emphasizing
the need to consider etiology at each step of diagnosis, as it often carries
significant treatment implications. It is likely that that this new classifica-
tion will assist in improving epilepsy care and research in many clinical
contests, surely including the TBI
Domenico d’Avella
Florinda Ferreri
Padova, Italy
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